USPTO Art Unit 1625 Prosecution Statistics

Art Unit Information

Art Unit: 1625
Group: 1620
Tech Center: 1600
Total Cases: 29,204
Last Active: October 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19352045BENZO NITROGEN-CONTAINING HETEROAROMATIC RING DERIVATIVE AND USE THEREOF IN MEDICINEOctober 2025December 2025Allow200NoNo
19327867MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOFSeptember 2025March 2026Allow611YesNo
19299954METHODS OF TREATING IDIOPATHIC PULMONARY FIBROSIS WITH DEUPIRFENIDONEAugust 2025March 2026Allow710NoNo
19299588CSF-1R INHIBITORS AND METHODS OF USE THEREOFAugust 2025November 2025Allow300NoNo
19287701MODULATORS OF TNF-ALPHA ACTIVITYJuly 2025October 2025Allow300NoNo
19268798METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERSJuly 2025September 2025Allow200NoNo
19258335ROUTE FOR CONSTRUCTING CHIRAL FRAGMENT OF FEZOLINETANT, INTERMEDIATE THEREOF, AND PREPARATION METHOD THEREFORJuly 2025December 2025Allow601YesNo
19254759ANDROGEN RECEPTOR PROTACSJune 2025December 2025Allow500NoNo
19256050HYDRATE OF VEGFR INHIBITOR, CRYSTAL FORM THEREOF AND PREPARATION METHOD THEREFORJune 2025February 2026Allow710NoNo
19253112TREATMENT OF MIGRAINEJune 2025February 2026Abandon810YesNo
19224580METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROMEMay 2025August 2025Allow310NoNo
19218915APPLICATION OF GENIPIN BETA-METHYL DERIVATIVE GEN-17 IN PREPARATION OF DRUG FOR PREVENTION AND TREATMENT OF ACUTE SEVERE PNEUMONIAMay 2025September 2025Allow310NoNo
19210905METHOD FOR CARBON DIOXIDE FIXATION USING A PALLADIUM-DOPED NITROGEN-RICH ORGANIC FRAMEWORK CATALYSTMay 2025August 2025Allow310NoNo
19094370SOLID STATE CRYSTALLINE FORMS OF A SELECTIVE POTASSIUM CHANNEL MODULATORMarch 2025April 2025Allow100YesNo
19092662TREATMENT OF MIGRAINEMarch 2025June 2025Allow300NoNo
19072750CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPYMarch 2025February 2026Allow1100NoNo
19055918TREATMENT OF MIGRAINEFebruary 2025July 2025Allow501YesNo
19048594DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USEFebruary 2025July 2025Allow621YesNo
19042453TREATMENT OF MIGRAINEJanuary 2025August 2025Allow711YesNo
19040329TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTHJanuary 2025May 2025Allow301YesNo
19024709USE OF REBOXETINE TO TREAT NARCOLEPSYJanuary 2025March 2025Allow200YesNo
19004230PARA ACYL SUBSTITUTED DIAZACYCLOHEXENE DERIVATIVESDecember 2024August 2025Abandon710NoNo
18988636METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROMEDecember 2024May 2025Allow510NoNo
18978995PROCESS FOR MAKING AN ISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOFDecember 2024April 2025Allow410YesNo
18958628MALATE SALT OF N-(4-{[6,7-BIS(METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCERNovember 2024February 2025Allow310NoNo
18956941COMPOSITIONS AND METHODS FOR TREATING CANCERNovember 2024June 2025Allow611NoNo
18945079TREATMENT OF MIGRAINENovember 2024June 2025Allow711YesNo
189255432,16-DIOXAPENTACYCLO[7.7.5.01,21.03,8.010,15]HENICOSA 3(8),10,12,14-TETRAENE-7,20-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2024June 2025Abandon810NoNo
18924415TREATMENT OF MIGRAINEOctober 2024March 2025Allow510NoNo
18919625DOSING REGIMEN FOR INJECTABLE CETIRIZINEOctober 2024February 2025Allow410NoNo
18904330KRAS Proteolysis Targeting ChimerasOctober 2024December 2025Allow1531NoNo
18903345PYRIDO[4,3-D]PYRIMIDINE COMPOUNDSOctober 2024December 2024Allow210YesNo
18895254METHOD FOR PREPARING 5-HYDROXYMETHYLFURFURALSeptember 2024February 2025Allow510NoNo
18889824PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF MIGRAINESeptember 2024December 2024Allow301YesNo
18827512CRYSTALLINE FORMS OF A MENIN INHIBITORSeptember 2024June 2025Allow920NoNo
18824811METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROMESeptember 2024November 2024Allow210YesNo
18820232USE OF REBOXETINE TO TREAT NARCOLEPSYAugust 2024March 2025Allow630YesNo
18809602CATALYSTS FOR SYNTHESIZING CYCLIC CARBONATES, PREPARATION METHODS AND USES THEREOFAugust 2024August 2025Allow1221NoNo
18809731DEVICE AND METHOD FOR PRODUCING HIGH-PRESSURE OR SUPER HIGH-PRESSURE STEAM AS BYPRODUCT FROM MALEIC ANHYDRIDE PRODUCING DEVICEAugust 2024April 2025Allow811YesNo
188072531-CYCLOPROPYL-6-FLUORO-7-(4-((5-(4-METHOXYBENZYLIDENEAMINO)-2-THIOXO-1,3,4- THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3- CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUNDAugust 2024November 2024Allow310NoNo
18804443PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOFAugust 2024October 2024Allow210NoNo
18802914CRYSTALLINE FORMS OF (E)-N-HYDROXY-3-(1-(PHENYLSULFONYL)INDOLIN-5-YL)ACRYLAMIDEAugust 2024September 2024Allow200NoNo
18802055PROCESS FOR THE HYDROGENATION OF CATNIP OILAugust 2024June 2025Allow1120NoNo
18795384METHODS FOR TREATING CANCERAugust 2024January 2025Allow510YesNo
18792999Oral Solutions Comprising Lisdexamfetamine SaltsAugust 2024July 2025Allow1121YesNo
18787536Systems and methods for the production of levulinic acid, furfural, and formic acidJuly 2024October 2024Allow200YesNo
187832312,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1July 2024February 2025Allow710NoNo
18783334CYCLOPROPANE SKELETON MONOPHOSPHINE LIGANDS, PALLADIUM COMPLEXES THEREOF, PREPARATION METHODS AND APPLICATIONJuly 2024March 2025Allow801NoNo
18778902METHOD FOR CONTINUOUSLY SYNTHESIZING 5-HYDROXYMETHYLFURFURAL BY USING MICRO-CHANNEL REACTORJuly 2024December 2024Allow510NoNo
18730722RESOLVIN ANALOGS COMPOUNDS, METHODS AND USES THEREOFJuly 2024February 2025Allow700NoNo
18776516TREATMENT OF MIGRAINEJuly 2024November 2024Allow401YesNo
18770589METHOD FOR SYNTHESIZING 1,3,2-DIOXATHIOLANE 2,2-DIOXIDE BY IN-SITU CATALYTIC OXIDATIONJuly 2024December 2024Allow510NoNo
18767083CRYSTAL FORMS OF 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATEJuly 2024December 2025Allow1700YesNo
18765229Process for production of essentially pure delta-9-tetrahydrocannabinolJuly 2024July 2025Allow1321NoNo
18765167SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAMEJuly 2024December 2024Allow510NoNo
18764612COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASESJuly 2024May 2025Allow1010YesNo
18756278COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERSJune 2024September 2025Allow1500NoNo
187475403-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERSJune 2024July 2025Allow1320NoNo
187462952-(HET)ARYL-SUBSTITUTED CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PEST CONTROL AGENTSJune 2024September 2025Abandon1510NoNo
18745768PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERSJune 2024June 2025Allow1210YesNo
18742346METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERSJune 2024April 2025Allow1010NoNo
18741969HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEONJune 2024January 2025Allow700YesNo
18739493METHODS OF PREPARING CANNABINOIDS OR DERIVATIVES THEREOFJune 2024December 2024Allow610NoNo
18734522METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMAJune 2024September 2025Abandon1621YesNo
18680940DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORSMay 2024April 2025Allow1010NoNo
18676200AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOFMay 2024April 2025Allow1120YesNo
18673671IONIZABLE CATIONIC LIPIDSMay 2024December 2025Allow1910NoNo
18670653LOW-TEMPERATURE CONTINUOUS-FLOW PREPARATION METHOD OF BEDAQUILINEMay 2024July 2024Allow200NoNo
18670680USING ADIPONECTIN RECEPTOR AGONISTS TO TREAT INFLAMMATION AND BONE DISEASES IN DIABETESMay 2024May 2025Allow1220YesNo
18667992TREATMENT OF PAIN AND NEUROLOGICAL CONDITIONSMay 2024February 2025Abandon910YesNo
18710113FERROPTOSIS INHIBITOR AND USE THEREFORMay 2024February 2025Allow911YesNo
18663549METHODS AND COMPOSITIONS COMPRISING A KRASG12C INHIBITOR AND A VEGF INHIBITOR FOR TREATING SOLID TUMORSMay 2024May 2025Allow1210NoNo
18663025TREATMENT OF MIGRAINEMay 2024July 2024Allow300YesNo
18657519READY-TO-ADMINISTER HYDROMORPHONE FORMULATIONSMay 2024September 2025Allow1601YesNo
18656965ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAMEMay 2024July 2025Allow1400NoNo
18655452PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDEMay 2024August 2025Allow1610YesNo
18656012ORGANIC COMPOUND (OXIME) TO COMBAT CHEMICAL WARFARE AGENTSMay 2024July 2025Allow1430NoNo
18654002BIMETALLIC METAL-ORGANIC FRAMEWORKS NANOSHEET BASED ON ZEOLITE IMIDAZOLE FRAMEWORK/MATERIALS OF INSTITUTE LAVOISIER TOPOLOGY AND PREPARATION METHOD AND APPLICATION THEREOFMay 2024October 2024Allow501NoNo
18644733Methods Of Treating Parkinson’s Disease and/or Lewy Body Disease or Disorder(s)April 2024May 2025Abandon1210YesNo
18642707PIPERIDINE COMPOUNDS AS PDE5 INHIBITORSApril 2024July 2024Allow200YesNo
18640883METHODS SUITABLE FOR THE TREATMENT OF ACNEApril 2024July 2025Allow1520YesNo
18637793COMPOUNDS FOR THE REDUCING LIPOTOXIC DAMAGEApril 2024February 2025Allow1010NoNo
18637529CRYSTAL FORM OF QUINOLINE COMPOUND AND PROCESS FOR ITS PRODUCTIONApril 2024May 2025Abandon1310NoNo
18635657ACETYLSALICYLIC ACID DERIVATIVE AND APPLICATION THEREOFApril 2024August 2025Allow1620YesNo
18633272TARGETED DEGRADATION OF VAV1April 2024August 2024Allow410NoNo
18699960COUPLED UREA MELAMINE PLANTApril 2024February 2025Allow1111NoNo
18628594METHODS OF TREATING NEUROLOGICAL DISORDERSApril 2024March 2025Allow1210NoNo
18617768NEUTROPHIL EXOCYTOSIS INHIBITORSMarch 2024August 2024Allow510YesNo
18615563MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODSMarch 2024March 2025Allow1210NoNo
18611561NANOMATERIALS COMPRISING TRIOLSMarch 2024December 2024Allow911NoNo
18606722SMALL MOLECULE COMPOUNDS HAVING NAPHTHYLAMINE STRUCTURE AND APPLICATION THEREOFMarch 2024September 2024Allow711NoNo
18692452APPLICATION OF PTGDS INHIBITOR IN PREPARATION OF DRUG FOR TREATING CATARACTSMarch 2024July 2024Allow400YesNo
18604727METHODS AND USES FOR TREATING ANHEDONIAMarch 2024October 2024Allow700YesNo
18603567WILD TYPE KIT INHIBITORSMarch 2024December 2024Allow921NoNo
18593308TREATMENT OF MIGRAINEMarch 2024October 2024Allow710NoNo
18592997VOLATILE APPLICATIONS AGAINST PATHOGENSMarch 2024August 2025Allow1710NoNo
18591732SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTSFebruary 2024May 2025Allow1501NoNo
18588874Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamideFebruary 2024December 2025Allow2211NoNo
18586669METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITYFebruary 2024April 2025Abandon1310NoNo
18585939Benzodioxane Modulators of Leukotriene A4 Hydrolase (LTA4H) for Prevention and Treatment of Aging-Associated DiseasesFebruary 2024August 2025Allow1711NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1625.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
110
Examiner Affirmed
60
(54.5%)
Examiner Reversed
50
(45.5%)
Reversal Percentile
90.9%
Higher than average

What This Means

With a 45.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
1227
Allowed After Appeal Filing
427
(34.8%)
Not Allowed After Appeal Filing
800
(65.2%)
Filing Benefit Percentile
62.5%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 34.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 1625 - Prosecution Statistics Summary

Executive Summary

Art Unit 1625 is part of Group 1620 in Technology Center 1600. This art unit has examined 29,204 patent applications in our dataset, with an overall allowance rate of 74.0%. Applications typically reach final disposition in approximately 22 months.

Comparative Analysis

Art Unit 1625's allowance rate of 74.0% places it in the 41% percentile among all USPTO art units. This art unit has a below-average allowance rate compared to other art units.

Prosecution Patterns

Applications in Art Unit 1625 receive an average of 1.29 office actions before reaching final disposition (in the 11% percentile). The median prosecution time is 22 months (in the 90% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.